Literature DB >> 17139643

Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.

Florence Tubach1, Thao Pham, Johan F Skomsvoll, Knut Mikkelsen, Olav Bjørneboe, Philippe Ravaud, Maxime Dougados, Tore K Kvien.   

Abstract

OBJECTIVE: The Patient Acceptable Symptomatic State (PASS) is the highest level of symptoms beyond which patients consider themselves well. It provides clinically meaningful information to interpret results from scales or questionnaires. Our goal was to determine the PASS in main outcome criteria when assessing patients with ankylosing spondylitis (AS) and to evaluate whether the PASS is stable over time.
METHODS: We used data from a randomized controlled trial of 330 patients with AS. The PASS was estimated at weeks 2, 6, and 12 for the following patient-reported outcomes: global pain (measured on a visual analog scale [VAS]), nocturnal pain (VAS), patient's global assessment of disease activity (VAS), disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), and functional impairment (Bath Ankylosing Spondylitis Functional Index [BASFI]). We used an anchoring method based on patients answering yes or no to, "Is your current condition satisfactory, when you take your general functioning and your current pain into consideration?" The PASS was defined as the 75th percentile of the score for patients who considered their state satisfactory. All patients were considered together in the analysis.
RESULTS: The values (95% confidence interval) of PASS were 33.5 (29.2-38.6) for pain, 28.0 (23.1-34.1) for night pain, 35.7 (31.3-41.1) for patient's global disease assessment, 31.4 (26.9-37.0) for BASFI, and 34.5 (30.9-38.9) for BASDAI. The PASS estimates were stable over time for all criteria during followup.
CONCLUSION: This study provides cutoff values for the PASS for the main outcome measures in AS and shows that PASS values are stable over time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17139643     DOI: 10.1002/art.22342

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

1.  Validity of the French version of the Core Outcome Measures Index for low back pain patients: a prospective cohort study.

Authors:  Stéphane Genevay; Marc Marty; Delphine S Courvoisier; Violaine Foltz; Geneviève Mahieu; Christophe Demoulin; Agnieszka Gierasimowicz Fontana; Michael Norberg; Pierre de Goumoëns; Christine Cedraschi; Sylvie Rozenberg
Journal:  Eur Spine J       Date:  2014-07-15       Impact factor: 3.134

2.  Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders.

Authors:  Florence Tubach; Philippe Ravaud; Dorcas Beaton; Maarten Boers; Claire Bombardier; David T Felson; Desireé van der Heijde; George Wells; Maxime Dougados
Journal:  J Rheumatol       Date:  2007-05       Impact factor: 4.666

Review 3.  [Ankylosing spondylitis. Target treatment criteria].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

4.  Investigating the patient acceptable symptom state cut-offs: longitudinal data from a community cohort using the shoulder pain and disability index.

Authors:  Gui Tran; Bright Dube; Sarah R Kingsbury; Alan Tennant; Philip G Conaghan; Elizabeth M A Hensor
Journal:  Rheumatol Int       Date:  2019-12-03       Impact factor: 2.631

Review 5.  Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?

Authors:  Tore K Kvien; Turid Heiberg; Kåre B Hagen
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

6.  Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care.

Authors:  Fausto Salaffi; Marina Carotti; Marwin Gutierrez; Marco Di Carlo; Rossella De Angelis
Journal:  Biomed Res Int       Date:  2015-06-18       Impact factor: 3.411

7.  Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.

Authors:  Maxime Dougados; Emily Wood; Bernard Combe; Thierry Schaeverbeke; Corinne Miceli-Richard; Francis Berenbaum; Nandan Koppiker; Arnaud Dubanchet; Isabelle Logeart
Journal:  Arthritis Res Ther       Date:  2014-11-27       Impact factor: 5.156

8.  The Foot Orthoses versus Hip eXercises (FOHX) trial for patellofemoral pain: a protocol for a randomized clinical trial to determine if foot mobility is associated with better outcomes from foot orthoses.

Authors:  Mark Matthews; Michael Skovdal Rathleff; Andrew Claus; Tom McPoil; Robert Nee; Kay Crossley; Jessica Kasza; Sanjoy Paul; Rebecca Mellor; Bill Vicenzino
Journal:  J Foot Ankle Res       Date:  2017-01-25       Impact factor: 2.303

9.  Clinical course and prognosis of musculoskeletal pain in patients referred for physiotherapy: does pain site matter?

Authors:  Nils-Bo de Vos Andersen; Peter Kent; Jakob Hjort; David Høyrup Christiansen
Journal:  BMC Musculoskelet Disord       Date:  2017-03-29       Impact factor: 2.362

10.  Good function after shoulder arthroplasty.

Authors:  Bjørg-Tilde S Fevang; Stein H L Lygre; Glenn Bertelsen; Arne Skredderstuen; Leif I Havelin; Ove Furnes
Journal:  Acta Orthop       Date:  2012-09-05       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.